Solaris (Eculizumab)
Purpose of Medication and Method of Action
This is the first drug approved for the treatment of PNH. PNH results from the breakdown of red blood cells which have developed abnormally. Symptoms of this condition include anemia requiring frequent transfusions, pain, fatigue, and debilitating weakness. Solaris inhibits a component of the system responsible for breaking down the red blood cells.
Solaris administration resulted in stabilization of blood hemoglobin concentrations and a significantly reduced need for blood transfusions. The potential for a serious meningococcal infection is a significant side effect. All patients requiring Solaris must be vaccinated against meningococcal infections.
Patient Medication Information
These information sheets do not list all known side effects of the medications, only the most common side effects. For a complete list of side effects please contact your local pharmacy or the actual drug manufacturing company.